uniQure NV (NASDAQ:QURE) shares fell 1.6% during trading on Friday . The stock traded as low as $6.96 and last traded at $7.16, with a volume of 125,485 shares. The stock had previously closed at $7.28.

Several analysts have issued reports on the stock. Jefferies Group reiterated a “buy” rating on shares of uniQure NV in a research note on Tuesday, May 31st. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of uniQure NV in a research note on Tuesday, May 31st. Chardan Capital reiterated a “buy” rating on shares of uniQure NV in a research note on Thursday, April 14th. Leerink Swann reiterated a “buy” rating on shares of uniQure NV in a research note on Sunday, June 12th. Finally, Cowen and Company reiterated a “buy” rating on shares of uniQure NV in a research note on Thursday. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $30.00.

The firm’s market cap is $180.43 million. The company’s 50-day moving average is $7.85 and its 200-day moving average is $12.35.

uniQure NV (NASDAQ:QURE) last announced its earnings results on Tuesday, May 31st. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.10. On average, equities research analysts forecast that uniQure NV will post ($3.44) earnings per share for the current year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.